

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202111004317 A

(19) INDIA

(22) Date of filing of Application :01/02/2021

(43) Publication Date : 23/09/2022

(54) Title of the invention : PHARMACEUTICAL COMPOSITION COMPRISING UBIQUITIN-PROTEASOME SYSTEM INHIBITOR FOR ATTENUATING SEIZURE DEVELOPMENT

| | | |
|---|---|--|
| (51) International classification | :A61K0009000000, A61K0047100000, A61K0038170000, A61K0047260000, A61K0009190000 | (71) Name of Applicant : 1)Chitkara Innovation Incubator Foundation Address of Applicant :SCO: 160-161, Sector - 9c, Madhya Marg, Chandigarh - 160009, India. Chandigarh India |
| (31) Priority Document No | :NA | (72) Name of Inventor : |
| (32) Priority Date | :NA | 1)SINGH, Thakur Gurjeet |
| (33) Name of priority country | :NA | 2)SINGH, Shareen |
| (86) International Application No | :NA | 3)DHIMAN, Sonia |
| Filing Date | :NA | |
| (87) International Publication No | : NA | |
| (61) Patent of Addition to Application Number | :NA | |
| Filing Date | :NA | |
| (62) Divisional to Application Number | :NA | |
| Filing Date | :NA | |

(57) Abstract :

The present disclosure provides a pharmaceutical composition comprising of N-benzyloxycarbonyl-leucyl-leucyl-phenylalanyl (Z-Leu-Leu-Phe-CHO), a selective inhibitor of ubiquitin proteasome system, which is found to have dose-dependent and marked attenuation of the seizure development including one or more conditions selected from the group consisting of acute seizure, repetitive seizures, and status epilepticus-induced spontaneous recurrent seizures. The present disclosure also provides a methods for producing injectable formulations compositions comprising of Z-Leu-Leu-Phe-CHO, pharmaceutically acceptable excipients and the like.

No. of Pages : 31 No. of Claims : 9